2014
DOI: 10.4314/ahs.v14i1.26
|View full text |Cite
|
Sign up to set email alerts
|

<i>In vitro</i> evidence of baicalein’s inhibition of the metabolism of zidovudine (AZT)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2018
2018

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…It also detoxifies drugs because glucuronidated metabolites possess less activity or toxicity than their parent forms [ 8 ]. Many cases of UGT inhibition-mediated drug interactions have been reported [ 5 , 7 ] including UGT1A1 inhibition by psoralidin that causes irinotecan’ toxicity [ 9 ], UGT1A3 inhibition by gemfibrozil that enhances susceptibility of statins [ 10 ], UGT1A6 inhibition by silybin that attenuates fenofibrate-induced UGT1A6 [ 11 ], UGT1A6 inhibition by phenobarbital and phenytoin that causes hepatotoxicity of acetamoniphen [ 12 , 13 ], UGT1A9 inhibition by mefenamic acid that changes exposure of dapagliflozin’s metabolite [ 14 ], and UGT2B7 inhibition by valproic acid that changes efficacy and toxicity of zidovudine [ 15 ]. Regulatory agencies have recognized the importance of UGT-mediated drug interactions in drug discovery research and patients’ safety [ 2 , 16 , 17 ].…”
Section: Introductionmentioning
confidence: 99%
“…It also detoxifies drugs because glucuronidated metabolites possess less activity or toxicity than their parent forms [ 8 ]. Many cases of UGT inhibition-mediated drug interactions have been reported [ 5 , 7 ] including UGT1A1 inhibition by psoralidin that causes irinotecan’ toxicity [ 9 ], UGT1A3 inhibition by gemfibrozil that enhances susceptibility of statins [ 10 ], UGT1A6 inhibition by silybin that attenuates fenofibrate-induced UGT1A6 [ 11 ], UGT1A6 inhibition by phenobarbital and phenytoin that causes hepatotoxicity of acetamoniphen [ 12 , 13 ], UGT1A9 inhibition by mefenamic acid that changes exposure of dapagliflozin’s metabolite [ 14 ], and UGT2B7 inhibition by valproic acid that changes efficacy and toxicity of zidovudine [ 15 ]. Regulatory agencies have recognized the importance of UGT-mediated drug interactions in drug discovery research and patients’ safety [ 2 , 16 , 17 ].…”
Section: Introductionmentioning
confidence: 99%